AstraZeneca plc (AZN) Cut to Sell at Beaufort Securities
Beaufort Securities lowered shares of AstraZeneca plc (LON:AZN) to a sell rating in a research report sent to investors on Friday. The brokerage currently has GBX 3,900 ($51.44) price target on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other research reports. Morgan Stanley reiterated an overweight rating and set a GBX 5,600 ($73.87) price objective on shares of AstraZeneca plc in a research report on Friday, June 23rd. Deutsche Bank AG reiterated a buy rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a research report on Thursday, May 4th. Barclays PLC reiterated an overweight rating and set a GBX 6,000 ($79.15) price objective on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Liberum Capital reiterated a buy rating and set a GBX 5,500 ($72.55) price objective on shares of AstraZeneca plc in a research report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of GBX 5,046.95 ($66.57).
AstraZeneca plc (AZN) opened at 4571.00 on Friday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The firm has a 50-day moving average of GBX 5,140.37 and a 200-day moving average of GBX 4,864.62. The firm’s market cap is GBX 57.87 billion.
The business also recently declared a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.91) per share. This represents a yield of 1.35%. The ex-dividend date is Thursday, August 10th.
In related news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.